These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 30291194)

  • 21. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.
    van Hulsteijn LT; Niemeijer ND; Dekkers OM; Corssmit EP
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):487-501. PubMed ID: 24118038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
    Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
    PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
    Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
    Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
    Lam MG; Lips CJ; Jager PL; Dullaart RP; Lentjes EG; van Rijk PP; de Klerk JM
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5888-95. PubMed ID: 16046591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of
    Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
    J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-specific-activity
    Dillon JS; Bushnell D; Laux DE
    Future Oncol; 2021 Apr; 17(10):1131-1141. PubMed ID: 33506713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
    Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
    Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C
    Clin Nucl Med; 2024 Jul; 49(7):610-620. PubMed ID: 38630996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of [
    Takenaka J; Watanabe S; Abe T; Hirata K; Uchiyama Y; Kimura R; Shinohara N; Kudo K
    Ann Nucl Med; 2023 Jan; 37(1):10-17. PubMed ID: 36301465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
    Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
    Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive Factors of Early 18F-Fluorodeoxyglucose-Positron Emission Tomography Response to [131I] Metaiodobenzylguanidine Treatment for Unresectable or Metastatic Pheochromocytomas and Paragangliomas.
    Takenaka J; Watanabe S; Abe T; Tsuchikawa T; Takeuchi S; Hirata K; Kimura R; Wakabayashi N; Shinohara N; Kudo K
    Neuroendocrinology; 2024; 114(9):816-826. PubMed ID: 37725921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences].
    Hasse-Lazar K; Krajewska J; Paliczka-Cieślik E; Jurecka-Lubieniecka B; Michalik B; Handkiewicz-Junak D; Roskosz J; Jarzab B
    Endokrynol Pol; 2008; 59(3):235-40. PubMed ID: 18615399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
    Carrasquillo JA; Chen CC; Jha A; Pacak K; Pryma DA; Lin FI
    J Nucl Med; 2021 Sep; 62(9):1192-1199. PubMed ID: 34475242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
    Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
    J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.
    Zhang X; Wakabayashi H; Kayano D; Inaki A; Kinuya S
    Nuklearmedizin; 2022 Jun; 61(3):231-239. PubMed ID: 35668668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.
    Loh KC; Fitzgerald PA; Matthay KK; Yeo PP; Price DC
    J Endocrinol Invest; 1997 Dec; 20(11):648-58. PubMed ID: 9492103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.